Skip to main content

Day: October 24, 2021

A statement on behalf of Loretta Rogers, Melinda Rogers-Hixon, Martha Rogers, John A. MacDonald, John Clappison, David Peterson, Bonnie Brooks, and Ellis Jacob

TORONTO, Oct. 24, 2021 (GLOBE NEWSWIRE) — We unequivocally support Joe Natale as CEO and support his management team. We along with the Management continue to work tirelessly on behalf of all stakeholders including customers, employees, and shareholders. We remain as duly elected members of the Rogers Communications Inc. Board and represent the majority of the Board members of the company. No other group of individuals has any authority to purport to act as the Board of Directors of Rogers Communications Inc.  About RogersRogers is a proud Canadian company dedicated to making more possible for Canadians each and every day. Our founder, Ted Rogers, purchased his first radio station, CHFI, in 1960. We have grown to become a leading technology and media company that strives to provide the very best in wireless, residential, sports,...

Continue reading

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting

REDWOOD CITY, Calif., Oct. 24, 2021 (GLOBE NEWSWIRE) — Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of six poster presentations at the upcoming American College of Gastroenterology (ACG) Annual Scientific Meeting. The presentations will take place during the ACG Annual Meeting being held in Las Vegas, Nev. and virtually Oct 22 to 27, 2021. Access to all accepted ePosters and ePresentations will be available on the ACG program website and in the October online supplement to the American Journal of Gastroenterology. EG and/or EoD Prevalence Data Presentations:Title(Presenter): Endoscopy and Systematic Biopsy of Patients With Moderate-Severe Unexplained Gastrointestinal Symptoms...

Continue reading

Kvika banki hf.: Kvika to acquire majority share in Ortus Secured Finance Ltd.

Kvika banki hf. (“Kvika”) has agreed heads of terms with the shareholders and the management team of Ortus Secured Finance Ltd. (“Ortus”) to acquire a majority shareholding in Ortus. Ortus is a British alternative credit provider specialising in property backed lending to borrowers in the United Kingdom. The company was founded in 2013 and currently manages a 23 billion ISK equivalent private credit portfolio, of which 14.5 billion ISK is held on Ortus’ own balance sheet. If the transaction proceeds, Kvika group’s total consolidated assets are expected to grow by 10%. Ortus’ headquarters are in London and the company also operates offices in Belfast, N-Ireland and in Glasgow, Scotland. Since its launch in 2013, Ortus has advanced over 70 billion ISK equivalent to borrowers whilst experiencing no losses of capital. Kvika, through its subsidiary...

Continue reading

Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting

Data from Phase 3 PHALCON-HP trial highlighted in oral presentation and recognized with the ACG Governors Award for Excellence in Clinical ResearchPhase 1 population PK data abstract concludes the large body of pre-existing clinical data related to vonoprazan in Asian populations can be reliably applied to non-Asian populationsReal-world physician and patient-based Study of Acid-Related Disorders (SOARD) provides perceptions of disease burden and highlights unmet needs in the treatment of H. pylori and erosive esophagitisFLORHAM PARK, N.J., Oct. 24, 2021 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today data from the PHALCON-HP Phase 3 study, the largest...

Continue reading

AEROMEXICO AIMS HIGHER WITH SUSTAINABLE AVIATION FUEL FLIGHTS

Mexico City, Oct. 24, 2021 (GLOBE NEWSWIRE) — • There will be three operations from San Francisco during the pilot phase. • These flights will reduce 27 tons of CO2 emissions. Mexico City, October 24, 2021.- As part of the International Day of Climate Action, Aeromexico will be operating its first flights between the U.S. and Mexico with sustainable aviation fuel (SAF), reducing 27 tons of CO2 emissions, equivalent to making more than 3,800 cars zero-emission for one day in Mexico City.   The flights will depart from San Francisco to Guadalajara and Mexico City, and they will be served in a Boeing 737-800 aircraft with GE/Safran CFM56 engines. For these trips, almost 40,000 liters of sustainable fuel made from waste animal fats and vegetable oils, as well as Jet-A jet fuel, were purchased. As the beginning of a long-term partnership,...

Continue reading

Proton Therapy contract finalized with Advocate Radiation Oncology Affiliate in Florida 

           Louvain-La-Neuve, Belgium, October 24, 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that its proton therapy contract with Advocate Radiation Oncology, via its affiliate Southwest Florida Proton, has been finalized. IBA will start to recognize revenue from the contract in 2021. The finalization of the contract follows the announcement earlier in the year that IBA had been selected by Advocate Radiation Oncology for its new radiation oncology center. The site will serve the greater population of Southwest Florida in a centralized location between Lee and Collier County. The contract involves the delivery of IBA’s Proteus®ONE* solution including Pencil Beam Scanning...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.